HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Maoshuo Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Cheelo…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Histone Deacetylase Inhibitors, Histone Deacetylases, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Taishan Scholar Project of Shandong Province, National Natural Science Foundation of China, Science Fund for Distinguished Young Scholars of Shandong Province.
Abstract (Originalsprache)
Herein, we identified that HDAC11 is involved in the pathogenesis of AML and is a potential therapeutic target for AML. Considering the scarcity of HDAC11 inhibitors, structurally novel HDAC11 inhibitors were developed, identifying A9 as the most potent one, which phenocopied the apoptosis induction, cell cycle arrest, and differentiation promotion effects of HDAC11 knockdown in AML cells. Moreover, A9 not only promoted iron uptake by upregulating TF and TFRC but also promoted iron release by upregulating HMOX1, which cooperatively led to iron homeostasis disruption and the consequent ferroptosis in AML cells. Mechanism investigation indicated that A9-induced HMOX1 upregulation was due to the activation of the p62-Keap1-Nrf2 pathway. Notably, the combination of A9 with chemotherapy drugs synergistically reduced AML cell viability in vitro. The robust in vivo anti-AML efficacy of A9, alone and combined with cytarabine, was also validated. Collectively, our study revealed pharmacological inhibition of HDAC11 as a potential therapeutic strategy for AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.…
- Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
- School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan, Hubei 430074, P.R. China.
ORCID-Profile: Maoshuo Yang, Yingjie Zhang
Förderung
- Taishan Scholar Project of Shandong Province
- National Natural Science Foundation of China
- Science Fund for Distinguished Young Scholars of Shandong Province
Zitieren
APA
Yang, M., Zhao, W., Zhang, J., Liu, L., Tian, S., Miao, Y., Jia, Y., Wang, L., Chai, Q., Wang, Q., Liu, F., Zhang, Y., & You, X. (2025). HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02550
Vancouver
Yang M, Zhao W, Zhang J, Liu L, Tian S, Miao Y, et al. HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02550
BibTeX
@article{Yang2025,
author = {Yang, Maoshuo and Zhao, Wei and Zhang, Jinwei and Liu, Lanlan and Tian, Sijia and Miao, Yaqing and Jia, Yongxin and Wang, Limei and Chai, Qipeng and Wang, Qiang and Liu, Fabao and Zhang, Yingjie and You, Xiaona},
title = {HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02550}
}
EUVIMED